ONYX (ONYX) fundamentals
ONYX is a listed company, part of the Pharmaceuticals sector, listed on the NSE as ONYX (ISIN INE0WVU01018). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What ONYX does
Onyx Biotec Ltd. is a pharmaceutical company engaged in the manufacture, sale, and distribution of generic and proprietary pharmaceutical products. It develops, manufactures and distributes generic and branded pharmaceutical products in various forms, like water for injection (WFI), dry powder injections, and dry powder syrup. WFI is a sterile preparation of water, which is supplied only in single-dose containers, indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection. Its dry powder injections include Ceftriaxone and Sulbactam for Injection, Cefazoline Sodium for Injection, and Cefepime and Tazobactam for Injection, among others. Its dry powder syrups include Cefpodoxime Proxetil, Cefuroxime Axetil, and others. Its core business is focused on providing end-to-end product development and manufacturing solutions to its clients. Its services also include preparation and filing of regulatory dossiers in the Indian and global markets.
Valuation and market data
| Last close | ₹38.00 |
|---|---|
| Market capitalisation | ₹57 crore |
| Enterprise value | ₹58 crore |
| P/E (TTM) | 3.53 |
| Price to book | 1.02 |
| Price to sales (TTM) | 0.28 |
| Book value per share | ₹37.19 |
| Dividend yield | 0.00% |
| Sector | Pharmaceuticals |
| Industry | — |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹70 crore | ₹-0 crore | ₹-0 crore | 0.00 |
| Mar 2025 | ₹63 crore | ₹6 crore | ₹5 crore | 3.31 |
| Mar 2024 | ₹54 crore | ₹4 crore | ₹4 crore | 3.05 |
| Mar 2023 | ₹40 crore | ₹3 crore | ₹2 crore | 1.56 |
| Mar 2022 | ₹45 crore | ₹4 crore | ₹3 crore | 2.84 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Mar 2026:
| Promoters | 65.1% |
|---|---|
| Foreign institutions (FII) | 1.1% |
| Mutual funds | 0.0% |
| Other domestic institutions | 2.4% |
| Retail and others | 31.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.